Endocrine Tumors of the Pancreas: Clinical Picture, Diagnosis, and Therapy

Surgery of the Liver, Biliary Tract and Pancreas: Volumes 1-2, Fourth Edition

Volumn 1, Issue , 2006, Pages 904-914

  Weber, K J ^a,b   Lin, J ^b   Prinz, R A ^c,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991662730     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3256-4.50069-7     Document Type: Chapter

References (89)

1. MA Anderson, et al. (2000) Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 95 2271-2277.
2. FG Banting and CH Best (1922) The internal secretion of the pancreas. J Lab Clin Med 7 251-266.
3. SW Becker, et al. (1942) Cutaneous manifestations of internal malignant tumors. Arch Dermatol Syphilol 45 1068-1080.
4. E Berber, et al. (2002) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26 985.
5. SR Bloom (1978) Vasoactive intestinal polypeptide, the major mediator of the WDHA (pancreatic cholera) syndrome: value of measurement in diagonosis and treatment. Am J Dig Dis 23 373.
6. JR Buscombe, et al. (2003) Long-term efficacy of high-activity 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 44 1-6.
7. RS Chamberlain, et al. (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190 432.
8. MA Chastain (2001) The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 321 306-320.
9. PNM Cheng and LB Saltz (1999) Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86 944-948.
10. JA Cherner and JL Sawyers (1992) Benefit of resection of metastatic gastrinoma in multiple endocrine neoplasia type I. Gastroenterology 102 1049-1053.
11. VD Corleto, et al. (2001) Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 15 1555-1561.
12. DN Danforth, et al. (1984) Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery 96 1027-1036.
13. T Delaunoit, et al. (2004) The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option? Eur J Cancer 40 515-520.
14. J Delvalle and T Yamada (1995) Zollinger-Ellison syndrome. T Yamada (Eds) Textbook of Gastroenterology Philadelphia: Lippincott 1430.
15. M di Bartolomeo, et al. (1996) Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: a study by the Italian Trials in Medical Oncology Group. Cancer 77 402-408.
16. B Dousset, et al. (1995) Metastatic endocrine tumors: is there a place for liver transplantation? Liver Transpl Surg 1 111-117.
17. N Ectors (1999) Pancreatic endocrine tumors: diagnostic pitfalls. Hepatogastroenterology 46 679.
18. EC Ellison and J Sparks (2003) Zollinger-Ellison syndrome in the era of effective acid suppression: are we unknowingly growing tumors? Am J Surg 186 245-248.
19. B Eriksson, et al. (2000) Tumor markers in neuroendocrine tumors. Digestion 62 33-38.
20. S Fabozzi (1903) Uber die histogenese des primaren krebes des pankres. Beitr Pathol 34 199-214.
21. S Faiss, et al. (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21 2689-2696.
22. M Fang, et al. (1979) Zollinger-Ellison syndrome with diarrhea as the predominant clinical feature. Gastroenterology 76 378-387.
23. SR Friesen (1982) Tumors of the endocrine pancreas. N Engl J Med 306 580-590.
24. SR Friesen (1987) Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am 67 379.
25. OP Ganda, et al. (1977) Somatostatinoma: a somatostatin-containing tumor of the pancreas. N Engl J Med 296 963-967.
26. F Gibril, et al. (1996) Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med 125 26-34.
27. H Gouya, et al. (2003) CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 181 987-992.
28. RA Gregory and HJ Tracy (1959) The preparation and properties of gastrin. J Physiol 149 70.
29. RA Gregory, et al. (1960) Extraction of a gastrin-like substance from a pancreatic tumor in a case of Zollinger-Ellison syndrome. Lancet 1 1045-1048.
30. L Grimelius, et al. (1975) Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchow Arch A Pathol Anat Histol 365 275.
31. GJ Harris, et al. (1987) Somatostatinoma: a case report and review of the literature. J Surg Oncol 36 8-16.
32. LA Hashimoto and RM Walsh (1999) Preoperative localization of insulinomas is not necessary. J Am Coll Surg 189 368-373.
33. JS Hiramoto, et al. (2001) Intraoperative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg 136 1020-1025.
34. B Hirshberg, et al. (2000) Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab 85 3222-3226.
35. SN Hochwald, et al. (2001) Nonfunctional pancreatic islet cell tumors. GM Doherty, B Skogseid (Eds) Surgical Endocrinology Philadelphia: Lippincott Williams & Wilkins 361-373.
36. TJ Howard, et al. (1990) Anatomic distribution of pancreatic endocrine tumors. Am J Surg 159 258.
37. DE Jaroszewski, et al. (2004) Laparoscopic localization and resection of insulinomas. Arch Surg 139 270-274.
38. RT Jensen (1999) Pancreatic endocrine tumors: recent advances. Ann Oncol 10(suppl), 6.
39. RT Jensen and JA Norton (1995) Endocrine neoplasms of the pancreas. T Yamada (Eds) Textbook of Gastroenterology Philadelphia: Lippincott 2131.
40. G Kaltsas, et al. (2004) Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 151 15-27.
41. AD King, et al. (1998) Dual phase spiral CT in the detection of small insulinomas of the pancreas. Br J Radiol 71 20-23.
42. KS Kirkwood and HT Debas (1995) Neuroendocrine tumors: common presentations of uncommon diseases. Compr Ther 21 719-725.
43. O Kisker, et al. (1997) The value of somatostatin receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors. J Am Coll Surg 184 487-492.
44. G Krejs, et al. (1979) Somatostatinoma syndrome: biochemical, morphologic, and clinical features. N Engl J Med 301 285-292.
45. SWJ Lamberts, et al. (1996) Octreotide. N Engl J Med 333 246-254.
46. P Langerhans (1869) Beitrage Zur Mikroskopischen Anatomie Der Bauchspeicheldruse Berlin: Gustar Lange
47. L Larsson, et al. (1977) Pancreatic somatostatinoma: clinical features and physiological implications. Lancet 1 666-668.
48. T Lehnert (1998) Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 66 1307-1312.
49. JY Mabrut, et al. (2001) Is preoperative localization of insulinomas necessary? Ann Chir 126 850-856. [French].
50. JC Mansour and H Chen (2004) Pancreatic endocrine tumors. J Surg Res 120 139-161.
51. C Mao, et al. (1995) Von Recklinghausen's disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol 59 67-73.
52. PN Maton, et al. (1985) Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N Engl J Med 312 17.
53. MH McGavran, et al. (1966) A glucagon-secreting alpha-cell carcinoma of the pancreas. N Engl J Med 274 1408-1413.
54. JE McGuigan and WL Trudeau (1968) Immunohistochemical measurements of elevated levels of gastrin in the serum of patients with pancreatic tumors of the Zollinger-Ellison variety. N Engl J Med 278 1038-1042.
55. E Mirallie, et al. (2002) Value of endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localization of insulinomas and gastrinomas: experience of 54 cases. Gastroenterol Clin Biol 26 360-366. [French].
56. CG Moertel, et al. (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303 1189-1194.
57. CG Moertel, et al. (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 519-523.
58. P Muscarella and EC Ellison (2004) Pancreatic islet cell tumors excluding gastrinoma. JL Cameron (Eds) Current Surgical Therapy 8th ed. Philadelphia: Mosby 520-524.
59. AG Nicholls (1902) Simple adenoma of the pancreas arising from an island of Langerhans. J Med Res 8 385-395.
60. JA Norton and RT Jensen (2004) Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 240 757-773.
61. JA Norton, et al. (1979) Amino acid deficiency and the skin rash associated with glucagonoma. Ann Intern Med 91 213-215.
62. JA Norton, et al. (1992) Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg 215 8-18.
63. JA Norton, et al. (1999) Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341 635-644.
64. JA Norton, et al. (2003) Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 138 859-866.
65. K Oberg (2000) Interferon in the management of neuroendocrine GEP-tumors. Digestion 62(suppl 1), 92-97.
66. K Oberg, et al. (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15 966-973.
67. TM O'Dorisio, et al. (1989) Medical therapy of VIPomas. Endocrinol Metab Clin N Am 18 545.
68. GQ Phan, et al. (1988) Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 2 472-482.
69. F Pignal, et al. (1982) Streptozotocin treatment in pancreatic cholera (Verner-Morrison) syndrome. Digestion 24 176-182.
70. JR Pisegna, et al. (1993) An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma. Gastroenterology 105 1179-1183.
71. RA Prinz (1986) Islet-cell tumors of the pancreas. Cresse et ResMedica 3 3-10.
72. RA Prinz, et al. (1981) Clinical aspects of glucagon-producing islet cell tumors. Am J Gastroenterol 76 125-131.
73. RA Prinz, et al. (1983) “Non-functioning” islet cell carcinoma of the pancreas. Am Surg 49 345-349.
74. C Proye, et al. (1998) Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery 124 1134-1143.
75. JM Sarmiento, et al. (2002) Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 132 976-982.
76. H Shojamanesh, et al. (2002) Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 94 331-343.
77. BE Stabile, et al. (1984) The gastrinoma triangle: operative implications. Am J Surg 147 25-31.
78. PW Stacpoole (1981) The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev 2 347.
79. P Stefanini, et al. (1974) Beta-islet cell tumors of the pancreas: results of a study on 1,067 cases. Surg 75 596-609.
80. DH Stephens (1997) CT of pancreatic neoplasms. Curr Probl Diagn Radiol 26 53-108.
81. JW Thomason, et al. (2000) Somatostatin receptor scintigraphy: the definitive technique for characterizing vasoactive intestinal peptide–secreting tumors. Clin Nucl Med 9 661-664.
82. JV Verner Jr and AB Morrison (1958) Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 25 374-380.
83. AO Vortmeyer, et al. (2004) Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 89 1934-1938.
84. RA Wermers, et al. (1966) The glucagonoma syndrome: clinical and pathologic features in 21 patients. Medicine (Baltimore) 75 53-63.
85. AO Whipple and VK Frantz (1935) Adenoma of islet cells with hyperinsulinism: a review. Ann Surg 101 1299-1335.
86. RM Wilder, et al. (1975) Carcinoma of the islands of the pancreas: hyperinsulinism and hypoglycemia. JAMA 93 204.
87. D Wynick, et al. (1989) Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol (Oxf) 30 385.
88. KA Yao, et al. (2001) Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130 677-682.
89. RM Zollinger and EH Ellison (1955) Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142 709-723.